News - Sunovion, Latuda

Filter

Current filters:

SunovionLatuda

Popular Filters

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Sunovion files two sNDAs for Latuda with FDA

09-09-2012

Sunovion Pharmaceuticals, a US subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506) has submitted…

Dainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients

30-10-2011

Sunovion Pharmaceuticals (SEPR: US) has announced results from a 12-month, double-blind extension study…

AstraZenecaLatudaNeurologicalPharmaceuticalResearchSeroquel XRSunovion

Back to top